Photocil (Topical) for the Treatment of Vitiligo

Completed · Not applicable · Has a placebo group

Conditions studied: Vitiligo

In brief

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of vitiligo.

Key facts

Study ID: NCT01992185
Run by: Applied Biology, Inc.
People needed: 15
Starts: 2013-08-01
Expected to finish: 2014-12-01
Last updated by the study team: 2016-03-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosed with vitiligo confirmed by a dermatologist
Vitiligo lesions affecting at a minimum 5% of the facial, legs, or arms surface area
Age: 18 to 65
Participants able to give informed consent

You may not qualify if…

Subject did not respond to prior phototherapy treatment
Subject completed phototherapy for same lesion(s) in last 6 months
Subject has previous history of skin cancer
Subject has previous history of photosensitivity
Subject has a history of herpes (HSV I or II) outbreaks
Subject has previous history of autoimmune disease may be excluded at investigator's discretion
Subject is currently taking of immunosuppressive or photosensitizing drugs
Subject plans to use antibiotics, anti-fungal, calcineurin inhibitors or other drugs that may cause photosensitivity during the study period. These patients may be excluded at investigator's discretion
Subject is pregnant or lactating women

Where it is running

Physicians Institute — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.